Loading company…
NeoCannBio develops medical cannabis ingredients, raw materials, and drugs.
Founded in 2021, NeoCannBio develops cannabinoid raw materials and extracts hemp ingredients using processing technology and equipment. It also develops medicines for difficult-to-treat and age-related diseases. The company is based in Seoul, South Korea, and raised KRW 10 billion in Series B funding in September 2023 from Bilanx Investment, Dong Hoon Investment, Prologue Ventures, QUAD Asset Management, BM Ventures, HLB Investment, and Medytox Venture Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in